克罗恩病患儿英夫利昔单抗治疗失应答预测方法研究进展  

Progress on predictive methods for loss of response to infliximab treatment in pediatric Crohn's disease

作　　者：岳阳 郭红梅[1] Yang Yue;Hongmei Guo(Department of Gastroenterology,Children's Hospital of Nanjing Medical University,Nanjing 210008,China;the Department of Pediatrics,the Second People's Hospital of Changzhou Affiliated to Nanjing Medical University,Changzhou 213000,China)

机构地区：[1]南京医科大学附属儿童医院消化内科,210008 [2]南京医科大学附属常州第二人民医院儿科,213000

出　　处：《国际儿科学杂志》2024年第4期236-239,共4页International Journal of Pediatrics

基　　金：南京市科学技术委员会重点项目(ZKX20042)。

摘　　要：英夫利昔单抗是目前治疗克罗恩病应用较广泛的生物制剂之一,但在实际应用过程中,部分患者会存在失应答,可能造成患者疾病难以控制以及治疗成本的增高。如何在早期鉴别出失应答已成为治疗的关键组成部分,但目前学术界尚无统一的预测标准。所以该文对近些年预测英夫利昔单抗治疗克罗恩病失应答的相关指标,如英夫利昔单抗浓度及抗抗体监测、血清学指标、超声、磁共振成像及内窥镜检查、克罗恩病临床指标、HLA-DQA1*05基因、新开发的模型和指标及其判断标准进行综述。Infliximab is one of the most extensively used biological agents in the treatment of Crohn's disease,but in the actual application process,some patients may have loss of response,which may lead to the refactory disease and the rise of treatment cost.Identifying loss of response at an early phase has become a crucial component of treatment,but the academic community has not a unified prediction standard yet.This article reviews the recent indicators for predicting loss of response to infliximab treatment,such as infliximab concentration and anti-antibody monitoring,serological indicators,ultrasound,magnetic resonance imaging and endoscopy,clinical indicators of Crohn's disease,HLA-DQA1*05 gene,newly developed models and indicators and their criteria.

关 键 词：英夫利昔单抗 克罗恩病 失应答 预测 

分 类 号：R725.7[医药卫生—儿科]